|
1
|
Rudolph E, Dyckhoff G, Becher H, Dietz A
and Ramroth H: Effects of tumour stage, comorbidity and therapy on
survival of laryngeal cancer patients: A systematic review and a
meta-analysis. Eur Arch Otorhinolaryngol. 268:165–179. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carvalho AL, Nishimoto IN, Califano JA and
Kowalski LP: Trends in incidence and prognosis for head and neck
cancer in the United States: A site-specific analysis of the SEER
database. Int J Cancer. 114:806–816. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang SY, Lu ZM, Luo XN, Chen LS, Ge PJ,
Song XH, Chen SH and Wu YL: Retrospective analysis of prognostic
factors in 205 patients with laryngeal squamous cell carcinoma who
underwent surgical treatment. PLoS One. 8:e601572013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schlessinger J: Common and distinct
elements in cellular signaling via EGF and FGF receptors. Science.
306:1506–1507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herchenhorn D and Ferreira CG: Targeting
epidermal growth factor receptor to optimize chemoradiotherapy in
locally advanced head and neck cancer: Has biology been taken into
account. J Clin Oncol. 29:e283–e287. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Specenier P and Vermorken JB: Cetuximab in
the treatment of squamous cell carcinoma of the head and neck.
Expert Rev Anticancer Ther. 11:511–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Almadori G, Bussu F, Gessi M, Ferrandina
G, Scambia G, Lauriola L, Paludetti G and Ranelletti FO: Prognostic
significance and clinical relevance of the expression of the HER
family of type I receptor tyrosine kinases in human laryngeal
squamous cell carcinoma. Eur J Cancer. 46:1144–1152. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kontić M, Milovanović J, Čolović Z, Poljak
NK, Šundov Ž, Sučić A and Pešutić-Pisac V: Epidermal growth factor
receptor (EGFR) expression in patients with laryngeal squamous cell
carcinoma. Eur Arch Otorhinolaryngol. 272:401–405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Young RJ, Rischin D, Fisher R, McArthur
GA, Fox SB, Peters LJ, Corry J, Lim A, Waldeck K and Solomon B:
Relationship between epidermal growth factor receptor status,
p16(INK4A), and outcome in head and neck squamous cell carcinoma.
Cancer Epidemiol Biomarkers Prev. 20:1230–1237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maroun CR and Rowlands T: The Met receptor
tyrosine kinase: A key player in oncogenesis and drug resistance.
Pharmacol Ther. 142:316–338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Graveel CR, Tolbert D and Woude GF Vande:
MET: A critical player in tumorigenesis and therapeutic target.
Cold Spring Harb Perspect Biol. 5:pii: a0092092013. View Article : Google Scholar
|
|
13
|
Park S, Choi YL, Sung CO, An J, Seo J, Ahn
MJ, Ahn JS, Park K, Shin YK, Erkin OC, et al: High MET copy number
and MET overexpression: Poor outcome in non-small cell lung cancer
patients. Histol Histopathol. 27:197–207. 2012.PubMed/NCBI
|
|
14
|
Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK,
Lee BL, Bang YJ and Kim WH: MET in gastric carcinomas: Comparison
between protein expression and gene copy number and impact on
clinical outcome. Br J Cancer. 107:325–333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Albiges L, Guegan J, Le Formal A, Verkarre
V, Rioux-Leclercq N, Sibony M, Bernhard JC, Camparo P, Merabet Z,
Molinie V, et al: MET is a potential target across all papillary
renal cell carcinomas: Result from a large molecular study of pRCC
with CGH array and matching gene expression array. Clin Cancer Res.
20:3411–3421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choe JY, Yun JY, Nam SJ and Kim JE:
Expression of c-Met Is different along the location and associated
with lymph node metastasis of head and neck carcinoma. Korean J
Pathol. 46:515–522. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carballeira A, Ginarte M, Diniz-Freitas M,
Fernández-Campos I, Gude F, Fraga M, Antúnez JR and
García-Caballero T: Immunohistochemical evaluation of EGFR
expression in lip squamous cell carcinoma. Correlation with
clinicopathological characteristics. Histol Histopathol.
29:641–648. 2014.PubMed/NCBI
|
|
18
|
Baschnagel AM, Williams L, Hanna A, Chen
PY, Krauss DJ, Pruetz BL, Akervall J and Wilson GD: c-Met
expression is a marker of poor prognosis in patients with locally
advanced head and neck squamous cell carcinoma treated with
chemoradiation. Int J Radiat Oncol Biol Phys. 88:701–707. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ghadjar P, Blank-Liss W, Simcock M, Hegyi
I, Beer KT, Moch H, Aebersold DM and Zimmer Y: MET
Y1253D-activating point mutation and development of distant
metastasis in advanced head and neck cancers. Clin Exp Metastasis.
26:809–815. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim CH, Koh YW, Han JH, Kim JW, Lee JS,
Baek SJ, Hwang HS and Choi EC: c-Met expression as an indicator of
survival outcome in patients with oral tongue carcinoma. Head Neck.
32:1655–1664. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seiwert TY, Jagadeeswaran R, Faoro L,
Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen
EE, Lingen MW, et al: The MET receptor tyrosine kinase is a
potential novel therapeutic target for head and neck squamous cell
carcinoma. Cancer Res. 69:3021–3031. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo J, Zha S, Gage WR, Dunn TA, Hicks JL,
Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, et al:
α-methylacyl-CoA racemase: A new molecular marker for prostate
cancer. Cancer Res. 62:2220–2226. 2002.PubMed/NCBI
|
|
23
|
Sawatsubashi M, Sasatomi E, Mizokami H,
Tokunaga O and Shin T: Expression of c-Met in laryngeal carcinoma.
Virchows Arch. 432:331–335. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bosch FX, Ritter D, Enders C,
Flechtenmacher C, Abel U, Dietz A, Hergenhahn M and Weidauer H:
Head and neck tumor sites differ in prevalence, and spectrum of p53
alterations but these have limited prognostic value. Int J Cancer.
111:530–538. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Götte K: Intratumoral genomic
heterogeneity in head and neck cancer. Laryngorhinootologie.
83:122–123. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Betts GN, Eustace A, Patiar S, Valentine
HR, Irlam J, Ramachandran A, Merve A, Homer JJ, Möller-Levet C,
Buffa FM, et al: Prospective technical validation and assessment of
intra-tumour heterogeneity of a low density array hypoxia gene
profile in head and neck squamous cell carcinoma. Eur J Cancer.
49:156–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moertel S, Ackermann H, Baghi M, Eckardt
A, Wagenblast J, Stöver T and Hambek M: Heterogeneity of primary
site biopsies in head and neck squamous cell carcinoma. Anticancer
Res. 31:665–669. 2011.PubMed/NCBI
|
|
28
|
Greene FL, Page DL, Fleming ID, et al:
AJCC Cancer Staging Manual. 6th. New York, NY: Springer; 2002,
View Article : Google Scholar
|
|
29
|
Carlsson J, Nordgren H, Sjöström J, Wester
K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H and Blomqvist
C: HER2 expression in breast cancer primary tumours and
corresponding metastases. Original data and literature review. Br J
Cancer. 90:2344–2348. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim CH, Moon SK, Bae JH, Lee JH, Han JH,
Kim K and Choi EC: Expression of hepatocyte growth factor and c Met
in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol.
126:88–94. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Patel M, Lu L, Zander DS, Sreerama L, Coco
D and Moreb JS: ALDH1A1 and ALDH3A1 expression in lung cancers:
Correlation with histologic type and potential precursors. Lung
Cancer. 59:340–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mazières J, Brugger W, Cappuzzo F, Middel
P, Frosch A, Bara I, Klingelschmitt G and Klughammer B: Evaluation
of EGFR protein expression by immunohistochemistry using H-score
and the magnification rule: Re-analysis of the SATURN study. Lung
Cancer. 82:231–237. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schaaij-Visser TB, Brakenhoff RH, Leemans
CR, Heck AJ and Slijper M: Protein biomarker discovery for head and
neck cancer. J Proteomics. 73:1790–1803. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim KY, Mcshane LM and Conley BA:
Designing biomarker studies for head and neck cancer. Head Neck.
36:1069–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Keren S, Shoude Z, Lu Z and Beibei Y: Role
of EGFR as a prognostic factor for survival in head and neck
cancer: A meta-analysis. Tumor Biol. 35:2285–2295. 2014. View Article : Google Scholar
|
|
36
|
Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H
and Carlsson J: EGFR, HER2, and HER3 expression in laryngeal
primary tumors and corresponding metastases. Ann Surg Oncol.
15:1193–1201. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Farhadieh RD, Salardini A, Rees CG,
Russell PJ, Yang JL and Smee R: Protein expression of epidermal
growth factor receptor in laryngeal squamous cell carcinoma index
tumors correlates with diagnosis of second primary tumors of the
upper aero-digestive tract. Ann Surg Oncol. 16:2888–2894. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma L, Wang D, Wufuer A, Wu R, Zhang S and
Wang R: Relationship between human papilloma virus infection and
expression of p16 and EGFR in head and neck squamous cell carcinoma
and their prognostic significance. Zhonghua Zhong Liu Za Zhi.
36:23–28. 2014.(In Chinese). PubMed/NCBI
|
|
39
|
Cao XJ, Hao JF, Yang XH, Xie P, Liu LP,
Yao CP and Xu J: Prognostic value of expression of EGFR and nm23
for locoregionally advanced nasopharyngeal carcinoma. Med Oncol.
29:263–271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marioni G, Blandamura S, Loreggian L,
Koussis H, Lionello M, Giacomelli L, Fasanaro E, Lovato A and
Staffieri A: Laryngeal carcinoma prognosis after postoperative
radiotherapy correlates with CD105 expression, but not with
angiogenin or EGFR expression. Eur Arch Otorhinolaryngol.
268:1779–1787. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bhardwaj V, Cascone T, Cortez MA, Amini A,
Evans J, Komaki RU, Heymach JV and Welsh JW: Modulation of c-Met
signaling and cellular sensitivity to radiation: Potential
implications for therapy. Cancer. 119:1768–1775. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Han CB, Ma JT, Li F, Zhao JZ, Jing W, Zhou
Y and Zou HW: EGFR and KRAS mutations and altered c-Met gene copy
numbers in primary non-small cell lung cancer and associated stage
N2 lymph node-metastasis. Cancer Lett. 314:63–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Goetsch L, Caussanel V and Corvaia N:
Biological significance and targeting of c-Met tyrosine kinase
receptor in cancer. Front Biosci (Landmark Ed). 18:454–473. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang Y, Zhao J and Zhang Q: The
expression and clinical significance of OPN and C-met in laryngeal
carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.
28:256–258. 2014.(In Chinese). PubMed/NCBI
|
|
45
|
Luan T and Yu Y: Increased hepatocyte
growth factor and c-Met receptor expression in nasopharyngeal
carcinoma. Int J Clin Exp Med. 7:5583–5587. 2014.PubMed/NCBI
|
|
46
|
Lim YC, Han JH, Kang HJ, Kim YS, Lee BH,
Choi EC and Kim CH: Overexpression of c-Met promotes invasion and
metastasis of small oral tongue carcinoma. Oral Oncol.
48:1114–1119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao D, Wang SH, Feng Y, Hua CG, Zhao J
and Tang XF: Intratumoral c-Met expression is associated with
vascular endothelial growth factor C expression, lymphangiogenesis,
and lymph node metastasis in oral squamous cell carcinoma:
Implications for use as a prognostic marker. Hum Pathol.
42:1514–1523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ishibe S, Karihaloo A, Ma H, Zhang J,
Marlier A, Mitobe M, Togawa A, Schmitt R, Czyczk J, Kashgarian M,
et al: Met and the epidermal growth factor receptor act
cooperatively to regulate final nephron number and maintain
collecting duct morphology. Development. 136:337–345. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Saunders VC, Lafitte M, Adrados I, Quereda
V, Feurstein D, Ling Y, Fallahi M, Rosenberg LH and Duckett DR:
Identification of an EGFRvIII-JNK2-HGF/c-Met-signaling axis
required for intercellular crosstalk and glioblastoma multiforme
cell invasion. Mol Pharmacol. 88:962–969. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Puri N and Salgia R: Synergism of EGFR and
c-Met pathways, cross-talk and inhibition, in non-small cell lung
cancer. J Carcinog. 7:92008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yamada T, Matsumoto K, Wang W, Li Q,
Nishioka Y, Sekido Y, Sone S and Yano S: Hepatocyte growth factor
reduces susceptibility to an irreversible epidermal growth factor
receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer
Res. 16:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Benedettini E, Sholl LM, Peyton M, Reilly
J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, et al:
Met activation in non-small cell lung cancer is associated with de
novo resistance to EGFR inhibitors and the development of brain
metastasis. Am J Pathol. 177:415–423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lau PC and Chan AT: Novel therapeutic
target for head and neck squamous cell carcinoma: HGF-MET signaling
pathway. Anticancer Drugs. 22:665–673. 2011. View Article : Google Scholar : PubMed/NCBI
|
